571170-89-3

Basic information

• Product Name: Cyclopent[b]indole-3-acetic acid, 5-bromo-4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-, methyl ester, (3R)-
• CAS NO: 571170-89-3
• Molecular Formula: C21H18BrClFNO2
• Molecular Weight: 450.735
• Mol File: 571170-89-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Cyclopent[b]indole-3-acetic acid, 5-bromo-4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-, methyl ester, (3R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopent[b]indole-3-acetic acid, 5-bromo-4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-, methyl ester, (3R)-(571170-89-3)
• EPA Substance Registry System: Cyclopent[b]indole-3-acetic acid, 5-bromo-4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-, methyl ester, (3R)-(571170-89-3)

Safety Data

• Hazardous Substances Data: 571170-89-3(Hazardous Substances Data)

Upstream product

• 393509-21-2 ethyl (7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate 
• 371-40-4 4-fluoroaniline 
• 1003-98-1 2-bromo-4-fluoroaniline 
• 61272-76-2 4-fluoro-2-iodoaniline 
• 20826-94-2 ethyl (2-oxocyclopentyl)acetate 
• 393509-05-2 [(3R)-5-bromo-4-(4-chlorobenzyl)-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid 
• 186581-53-3 diazomethane 
• 393509-04-1 [5-bromo-4-(4-chlorobenzyl)-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid 
• 571170-85-9 (5-bromo-7-fluoro-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)-acetic acid methyl ester 
• 571170-84-8 [2-(2-bromo-4-fluoro-phenylimino)-cyclopentyl]-acetic acid ethyl ester 
• 393509-23-4 (5-bromo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid 
• 393509-22-3 (+/-) 2-(7-fluoro-1,2,3-trihydrocyclopenta[2,3-b]indol-3-yl)acetic acid 

Downstream Products

• 571170-92-8 [4-(4-chloro-benzyl)-7-fluoro-5-methanesulfonyl-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]-acetic acid methyl ester 
• 929039-04-3 [4-(4-chloro-benzyl)-7-fluoro-5-methanesulfonyl-1-oxo-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]-acetic acid methyl ester 
• 1027400-35-6 methanesulfonic acid 5-acetyl-4-(4-chloro-benzyl)-7-fluoro-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-ylmethyl ester 
• 1026405-15-1 acetic acid 5-acetyl-4-(4-chloro-benzyl)-7-fluoro-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-ylmethyl ester 
• 1026726-96-4 methanesulfonic acid 5-bromo-4-(4-chloro-benzyl)-7-fluoro-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-ylmethyl ester 
• 1009099-48-2 1-((3S)-5-bromo-4-(4-chlorobenzyl)-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)ethane-1,2-diol 
• 1026032-05-2 acetic acid 5-bromo-4-(4-chloro-benzyl)-7-fluoro-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-ylmethyl ester 
• 1009099-50-6 1-((3S)-4-(4-chlorobenzyl)-7-fluoro-3-(hydroxymethyl)-1,2,3,4-tetrahydrocyclo-penta[b]indol-5-yl)ethanone 
• 1009099-49-3 ((3S)-5-bromo-4-(4-chlorobenzyl)-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)methanol 
• 571170-77-9 laropiprant 
• 794535-36-7 [5-acetyl-4-(4-chloro-benzyl)-7-fluoro-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]-acetic acid 
• 936337-07-4 methyl [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-acetyl-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetate 
• 571170-90-6 [5-bromo-4-(4-chloro-benzyl)-7-fluoro-1-oxo-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]-acetic acid methyl ester 

Relevant articles and documents

Practical (14C)-synthesis of molecules containing an acetic acid moiety: Application to (14C)-labeled DP1 antagonists

Efficient carbon-14 labeling of four potent and selective DP1 antagonists is reported. The synthetic sequence began with α-hydroxylation, reduction of an ester, followed by oxidative diol cleavage and aldehyde reduction. The resulting alcohol 4 was conver

Method of Treating Pathological Blushing

A method of treating pathological blushing is disclosed wherein the patient is administered a DP receptor antagonist. Compositions containing DP antagonists are also included.

METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS

A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent